Journals / Klinik Tıp Pediatri Dergisi / 2017 / Cilt: 9 - Sayı: 2

New Development Models in Immunotherapy

Yeni Geliştirilen İmmunoterapi Modelleri

Pages
171–177
Publication Date
2017-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article reviews new developed immunotherapy materials and administration methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractIn the treatment of allergic diseases, allergen specific immunotherapy (SIT) is theonly specific treatment method that provide cure and long term protective effect.
📊
Key Findings & Data:Although SIT have been used over the past one hundred years, there are still some problems about side effects and efficacy of immunotherapy.
💡
Conclusion & Impact:This article reviews new developed immunotherapy materials and administration methods.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Alerji · immunoterapi · intralenfatik

Abstract

AbstractIn the treatment of allergic diseases, allergen specific immunotherapy (SIT) is theonly specific treatment method that provide cure and long term protective effect. Although SIT have been used over the past one hundred years, there are still some problems about side effects and efficacy of immunotherapy. Furthermore taking a longtime of treatment causes loss of labor and time, hence new studies on allergen models and use of administration of SIT is made. In all of these administrations the standardization of allergen extract which has the most effective immun stimulation concentration and lowest observed adverse effect level is important. There is a need forresearch about long term efficacy, safety, prevention asthma and new allergen sen-sitization of new developed immunotherapy models and allergen extract. This article reviews new developed immunotherapy materials and administration methods.

Özet

ÖzAlerjen spesifik immünoterapi (SİT), alerjik hastalıkların tedavisinde kür sağlayan ve uzun süre koruyucu etkisi olan tek spesifik tedavi yöntemidir. Yüz yılı aşkınsüredir alerjik hastalıkların tedavisinde kullanılmasına rağmen günümüzde halen immunoterapi etkinliği ve yan etkilerine dair problemler yaşanmaktadır. Aynı zamanda uzun tedavi süresinin işgücü ve zaman kaybına yol açması, SİT için yeni uygulama yolları ve alerjen modelleri üzerinde çalışmalar yapılmasına neden olmaktadır.Tüm bu uygulamaların hepsinde immün sistemi en iyi uyarabilecek en az yan etkiye sahip doz ve konsantrasyonda alerjen ekstresinin standardizasyonu önem taşımaktadır. Yeni geliştirilen immunoterapi modelleri ve alerjen ekstrelerinin uzun dönemetkinlik, güvenilirlik, astım gelişiminin ve yeni alerjik duyarlanmaların önlenmesikonusunda yapılacak çalışmalara ihtiyaç bulunmaktadır. Bu makalede yeni geliştirilen immünoterapi materyalleri ve yeni uygulama yöntemlerinden sözedilecektir.

🔖

Cite This Article

ALTINTAŞ, D. D. U. (2017). New Development Models in Immunotherapy. Klinik Tıp Pediatri Dergisi, Cilt: 9 - Sayı: 2, 171–177. https://ajindex.com/articles/838436

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kaynaklar 1.Noon L. Prophylactic inoculation against hay fever. Lancet1911;1:1572-3. 2.Freeman J. Further observations on the treatment of hay fever byhypodermic inoculations of pollen vaccine. Lancet 1911;2:814- 7 3.Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical pro-perties of human reaginic antibody. Presence of a uniquc immu-noglobulin as a career of reaginic antibody. J Immunol1966;97:75 4.Rocklin RE. Clinical and immunology aspects of allergen speci-fic immunotherapy in patients with seasonal allergic rhinitis and/ or allergic asthma. J Allergy Clin Immunol 1983;72:323 5.Hochfelder JL, Ponda P. Allergen immunotherapy:routes, safety,efficacy, and mode of action. Immuno Targets and Therapy2013;2:61-71 6.Jutel M, Agache I, Bonini S, Burks AW, Calderon M, CanonicaW et al. International consensus on allergy immunotherapy. J Al-lergy Clin Immunol 2015;136:556-68. 7.Scadding GK, Brostoff J. Low dose sublingual therapy in pati-ents with allergic rhinitis due to dust mite. Clin Allergy1986;16:483- 91. 8.Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I,et al. Allergen immunotherapy: a practice parameter third up-date. J Allergy Clin Immunol 2011;127 (1 Suppl):1-55 9.Allam JP, Niederhagen B, Bucheler M, Appel T, Betten H, Bie-ber T et al. Comparative analysis of nasal and oral mucosa den-dritic cells. Allergy 2006; 61:166-72. 10.Jutel M, Agache I, Bonini S, Burks AW, Calderon M, CanonicaW, et al. International consensus on allergy immunotherapy. JAllergy Clin Immunol 2015;136(3):556-6811.Özdemir C, Bahçeciler N, Barlan I. Sublingual İmmunoterapi.Güncel Pediatri 2006; 3: 137-139. 12.Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di LorenzoG. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012; 130(5):1097–1107. e1092. 13.Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de BeaumontO, Le Gall M; SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhi-noconjunctivitis. J Allergy Clin Immunol. 2009 Jan;123(1):160-166. 14.Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Kli-mek L, et al. Safety and efficacy in children of an SQ-standardi-zed grass allergen tablet for sublingual immunotherapy. J AllergyClin Immunol. 2009 Jan;123(1):167-173.15.de Groot H, Bijl A. Anaphylactic reaction after the first dose ofsublingual immunotherapy with grass pollen tablet. Allergy.2009;64